These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30231128)

  • 21. Reducing costs while enhancing quality of care in MS.
    Kister I; Corboy JR
    Neurology; 2016 Oct; 87(15):1617-1622. PubMed ID: 27590294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple sclerosis, a treatable disease .
    Doshi A; Chataway J
    Clin Med (Lond); 2017 Dec; 17(6):530-536. PubMed ID: 29196354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical and epidemiologic characteristics of 20 patients with multiple sclerosis in Cuiabá-Mato Grosso, Brazil].
    Grzesiuk AK
    Arq Neuropsiquiatr; 2006 Sep; 64(3A):635-8. PubMed ID: 17119809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of disease-modifying agents in multiple sclerosis--by the Canadian Network of MS Clinics.
    O'Connor P; Devonshire V;
    Can J Neurol Sci; 2008 May; 35(2):127-32. PubMed ID: 18574923
    [No Abstract]   [Full Text] [Related]  

  • 25. Established disease-modifying treatments in relapsing-remitting multiple sclerosis.
    Oh J; O'Connor PW
    Curr Opin Neurol; 2015 Jun; 28(3):220-9. PubMed ID: 25923124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple sclerosis: new insights in pathogenesis and novel therapeutics.
    Ontaneda D; Hyland M; Cohen JA
    Annu Rev Med; 2012; 63():389-404. PubMed ID: 21888515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity.
    Longbrake EE; Cross AH
    JAMA Neurol; 2016 Feb; 73(2):219-25. PubMed ID: 26720195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [An update on the treatment options for multiple sclerosis].
    Niino M
    Brain Nerve; 2012 Dec; 64(12):1421-6. PubMed ID: 23209069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects.
    Vidal-Jordana A; Montalban X
    Neuroimaging Clin N Am; 2017 May; 27(2):195-204. PubMed ID: 28391781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Towards immunotherapeutic drugs and vaccines against multiple sclerosis.
    Katsara M; Matsoukas J; Deraos G; Apostolopoulos V
    Acta Biochim Biophys Sin (Shanghai); 2008 Jul; 40(7):636-42. PubMed ID: 18604455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm.
    Giovannoni G
    Curr Opin Neurol; 2018 Jun; 31(3):233-243. PubMed ID: 29634596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Progress in the treatment of multiple sclerosis].
    Chan A; Kamber N; Hoepner R; Salmen A
    Ther Umsch; 2018; 75(7):405-409. PubMed ID: 30935353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoeconomics of synthetic therapies for multiple sclerosis.
    D'Amico E; Chisari CG; Gitto L; Zanghì A; Toscano S; Patti F
    Expert Opin Pharmacother; 2019 Aug; 20(11):1331-1340. PubMed ID: 31090469
    [No Abstract]   [Full Text] [Related]  

  • 34. Multiple sclerosis disease-modifying therapy prescribing patterns in Ontario.
    Marriott JJ; Mamdani M; Saposnik G; Gomes T; Manno M; O'Connor PW
    Can J Neurol Sci; 2013 Jan; 40(1):67-72. PubMed ID: 23250130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers.
    Oliveira EM; Simm RF; Dasic G; Morais MM; Perreira SL; Callegaro D
    Arq Neuropsiquiatr; 2015 Sep; 73(9):736-40. PubMed ID: 26352489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching therapies in MS: what are the options?
    Markowitz CE
    J Clin Psychiatry; 2015 Feb; 76(2):e6. PubMed ID: 25742221
    [No Abstract]   [Full Text] [Related]  

  • 37. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Choosing the best treatment for multiple sclerosis: comparative effectiveness, safety, and other factors involved in disease-modifying therapy choice.
    Happe LE
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s332-42. PubMed ID: 24494634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The future of multiple sclerosis treatments.
    Coclitu C; Constantinescu CS; Tanasescu R
    Expert Rev Neurother; 2016 Dec; 16(12):1341-1356. PubMed ID: 27682738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016.
    García Merino A; Ramón Ara Callizo J; Fernández Fernández O; Landete Pascual L; Moral Torres E; Rodríguez-Antigüedad Zarrantz A
    Neurologia; 2017 Mar; 32(2):113-119. PubMed ID: 27157522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.